FortuneXp November Stock Picks

Had a dull year so far? These 3 stocks will cheer you up.

Dear Investor,

Welcome to FortuneXp!

We bring to you three stocks from different sectors that can easily generate 20-40% returns within a short time frame of two months. These fundamentally sound companies are safe for trading in the short term and have the potential to generate multibagger returns in your portfolio if held for 3-5 years.


WABAG is one of the world’s leading companies in the water treatment field. WABAG’s key competences, which are based on over 90 years of plant building experience, lie in the design, completion and operation of drinking water and wastewater plants for both the municipal and industrial sectors. WABAG offers sustained solutions for special customer needs through a comprehensive range of services and innovative technologies.

The stock has formed a descending triangle reversal pattern after a long period of correction and consolidation and is now ready to hit new highs within a couple of months.
Big image


KEC International Limited is India's second largest manufacturer of electric power transmission towers and one of the largest Power Transmission Engineering, Procurement & Construction (EPC) companies in the world. It is headquartered in Mumbai, India and is part of the ₹160 billion (US$2.4 billion) RPG Group, engaged in laying of power transmission lines on EPC globally. It also provides telecom infrastructure services, tower testing, satellite and GPRS surveys, and hotline stringing services. It has operations in Algeria, Afghanistan, Egypt, Ethiopia, Ghana, Kazakhstan, Kenya, Mali, Mozambique, Namibia, Nigeria, Saudi Arabia, South Africa, Tajikistan, and the United Arab Emirates.

We are seeing a symmetrical triangle breakout in KEC which will take it above 180 levels within a few weeks.

Big image

Marksans Pharma

Marksans Pharma, incorporated in 1992, was a wholly–owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005. Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others. The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.

A smallcap pharma stock that's been consolidating from quite some time and is about to give a breakout soon.
Big image